Blood Flow Speed, Coronary Flow Velocity
Conditions
Keywords
Ticagrelor, Healthy, Coronary flow velocity, Adenosine
Brief summary
The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.
Interventions
DRUGAZD6140
P2Y12 receptor antagonist
DRUGPlacebo
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Suitable for ECG recording of CBFV and have no adverse reaction to adenosine challenge * Have a body mass index between 18 and 30 kg/m2
Exclusion criteria
* History of clinically significant disease or disorder. * Abnormal vital signs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity response by estimating the change in area under the adenosine dose response curve before and after study drug. | During 6 h at visit 2 |
Secondary
| Measure | Time frame |
|---|---|
| Effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity by estimating the change in area under the adenosine dose response curve before and after infusion of theophylline. | During 6 h at visit 2 |
| Difference in basal blood flow (in the absence of adenosine) between Ticagrelor and placebo conditions before and after infusion of theophylline. | During 6h at visit 2 |
Countries
Sweden
Outcome results
None listed